Results 51 to 60 of about 23,603,276 (341)

Restoration of cytomegalovirus antigen presentation by gamma interferon combats viral escape. [PDF]

open access: yes, 1994
An immediate-early protein of murine cytomegalovirus (MCMV), pp89, elicits an immunodominant and protective major histocompatibility complex (MHC) class I Ld-restricted CD8+ T-lymphocyte response.
Stipan Jonjic   +11 more
core   +1 more source

An Overview on ERAP Roles in Infectious Diseases

open access: yesCells, 2020
Endoplasmic reticulum (ER) aminopeptidases ERAP1 and ERAP2 (ERAPs) are crucial enzymes shaping the major histocompatibility complex I (MHC I) immunopeptidome. In the ER, these enzymes cooperate in trimming the N-terminal residues from precursors peptides,
Irma Saulle   +3 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Presentation of CMV immediate-early antigen to cytolytic T lymphocytes is selectively prevented by viral genes expressed in the early phase [PDF]

open access: yes, 1989
The regulation of antigen processing and presentation to MHC class I-restricted cytolytic T lymphocytes was studied in cells infected with murine cytomegalovirus. Recognition by cytolytic T lymphocytes of the phosphoprotein pp89, the immunodominant viral
Reddehase, Matthias J.   +7 more
core   +1 more source

Palmitoylated antigens for the induction of anti-tumor CD8+ T cells and enhanced tumor recognition

open access: yesMolecular Therapy: Oncolytics, 2021
Induction of tumor-specific cytotoxic CD8+ T cells (CTLs) via immunization relies on the presentation of tumor-associated peptides in major histocompatibility complex (MHC) class I molecules by dendritic cells (DCs).
Dorian A. Stolk   +12 more
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

open access: yesMolecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim   +3 more
wiley   +1 more source

HLA class I-restricted minor histocompatibility antigens.

open access: yes, 2016
HLA class I-restricted minor histocompatibility antigens.
Marieke Griffioen (119817)   +3 more
core   +1 more source

Recognition of Human Histocompatibility Leukocyte Antigen (HLA)-E Complexed with HLA Class I Signal Sequence–derived Peptides by D94/NKG2 Confers Protection from Natural Killer Cell–mediated Lysis [PDF]

open access: yes, 1998
Human histocompatibility leukocyte antigen (HLA)-E is a nonclassical HLA class I molecule, the gene for which is transcribed in most tissues. It has recently been reported that this molecule binds peptides derived from the signal sequence of HLA class I ...
John E. Coligan   +14 more
core   +1 more source

Prevalence and Specificity of Anti-HPA and Anti-HLA Antibodies in Patients with Suspected Immune-Mediated Platelet Disorders: A Single-Center Study from Serbia

open access: yesMedicina
Background and Objectives: Alloantibodies directed against human platelet antigens and human leukocyte antigens are implicated in several immune-mediated platelet disorders, including platelet transfusion refractoriness, post-transfusion purpura and ...
Svetlana Vojvodić, Jasmina Grujić
doaj   +1 more source

The Clinical Application of Neoantigens in Esophageal Cancer

open access: yesFrontiers in Oncology, 2021
Esophageal cancer (EC) is a common malignant tumor with poor prognosis, and current treatments for patients with advanced EC remain unsatisfactory. Recently, immunotherapy has been recognized as a new and promising approach for various tumors.
Yi-Min Gu   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy